Gottfried H W, Maier S, Brändle E, Kleinschmidt K, Hautmann R
Urologische Universitätsklinik Ulm.
Urologe A. 1997 Sep;36(5):413-9. doi: 10.1007/s001200050119.
Minimally invasive treatment of urinary incontinence has become a subject of major interest in recent years. We examined the use of transurethral collagen injection for incontinence treatment. A total of 48 patients were selected for this procedure from April 1993 to February 1997-26 male patients (19 post-RPX incontinence and 7 post-TUR incontinence) and 22 female patients (all after previous incontinence surgery) were treated by injection of collagen into the continence region. The whole group underwent an average of 1.8 sessions, and a mean collagen injection volume of 14.5 ml was delivered per session. Mean follow-up was 9.2 months. Of the female population, 68.2% were cured or greatly improved. In the male population only 47.3% of the post-RPX patients and 6/7 of the post-TUR patients benefited from the procedure. In males, treatment outcome depends on the degree of pretreatment incontinence, because all grade III incontinence patients did worse. Therefore we conclude: transurethral collagen injection is an interesting method in the treatment of urinary incontinence if proper patient selection is assured.
近年来，尿失禁的微创治疗已成为一个备受关注的课题。我们研究了经尿道注射胶原蛋白治疗尿失禁的方法。1993年4月至1997年2月，共有48例患者接受了该治疗——26例男性患者（19例为经耻骨后前列腺切除术（RPX）后尿失禁，7例为经尿道前列腺电切术（TUR）后尿失禁）和22例女性患者（均为既往有尿失禁手术史）通过向控尿区域注射胶原蛋白进行治疗。整个组平均接受了1.8次治疗，每次治疗平均注射胶原蛋白量为14.5毫升。平均随访时间为9.2个月。在女性患者中，68.2%治愈或明显改善。在男性患者中，只有47.3%的RPX术后患者和6/7的TUR术后患者从该治疗中获益。对于男性患者，治疗效果取决于术前尿失禁的程度，因为所有III级尿失禁患者的治疗效果较差。因此我们得出结论：如果能确保正确选择患者，经尿道注射胶原蛋白是治疗尿失禁的一种有效方法。
